Literature DB >> 21366706

Clinical and laboratory study of ocular rosacea in northern Greece.

E Lazaridou1, C Fotiadou, N G Ziakas, C Giannopoulou, Z Apalla, D Ioannides.   

Abstract

BACKGROUND: The prevalence of ophthalmic involvement in rosacea is probably higher than previously presumed and varies considerably among several studies.
OBJECTIVE: This study aimed to determine the incidence of ocular disease among a population of rosacea patients in Northern Greece, to objectively determine the presence of eye dryness in rosacea patients with and without clinical ophthalmic involvement and correlate the severity of ocular disease with the severity of cutaneous rosacea.
METHODS: One hundred patients with rosacea were assessed for the stage of their disease and examined for ocular symptoms and signs. In 24 of them the tear break up time (TBUT) and Schirmer test were performed in each eye, along with 24 controls.
RESULTS: A total of 33 patients (33%) were positive for ophthalmic findings. The most frequent symptoms and signs were burning sensation and tearing, and conjunctivitis and blepharitis, respectively. Eleven patients with ophthalmic manifestations had mild to moderate erythematotelangiectatic rosacea, 17 had moderate papulopustular rosacea and four exhibited findings of phymatous rosacea. The total mean value of patients' Schirmer tests was significantly lower compared with the healthy controls (P < 0.0001). Mean TBUT was shorter in the rosacea group than that in the age-matched controls (P < 0.0001).
CONCLUSION: Ocular involvement in rosacea is a common phenomenon with eye dryness being an early sign. Tear function tests, like Schirmer test and TBUT, although not specific, could contribute to the screening and early diagnosis of the disease, to prevent the potential development of sight-threatening conditions.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2011        PMID: 21366706     DOI: 10.1111/j.1468-3083.2011.03995.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

1.  Ocular rosacea: an underdiagnosed cause of relapsing conjunctivitis-blepharitis in the elderly.

Authors:  Sergio Umberto De Marchi; Emanuela Cecchin; Sergio De Marchi
Journal:  BMJ Case Rep       Date:  2014-09-19

2.  Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline.

Authors:  Aysegul Arman; Duriye Deniz Demirseren; Tamer Takmaz
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

Review 3.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

4.  Prevalence of rosacea in the general population of Germany and Russia - The RISE study.

Authors:  J Tan; H Schöfer; E Araviiskaia; F Audibert; N Kerrouche; M Berg
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-03       Impact factor: 6.166

5.  Development of an animal model for rosacea‑like skin lesions caused by Demodex.

Authors:  Xue Luo; Nan Zhou; Lanxi Wu; Zhujun Wang; Jianhong Zhang; Xiuli Luan; Yang Luo
Journal:  Exp Ther Med       Date:  2022-08-08       Impact factor: 2.751

6.  Corneal and conjunctival sensitivity in rosacea patients.

Authors:  Nurgül Örnek; Ayşe Anıl Karabulut; Kemal Örnek; Zafer Onaran; Gülşah Usta
Journal:  Saudi J Ophthalmol       Date:  2015-09-11

7.  Development and Evaluation of a Rosacea Screening Instrument (Rosascreen).

Authors:  Jerry Tan; James Leyden; Bernard Cribier; Fabien Audibert; Nabil Kerrouche; Mats Berg
Journal:  J Cutan Med Surg       Date:  2016-02-01       Impact factor: 2.092

8.  The Rosacea-specific Quality-of-Life instrument (RosQol): Revision and validation among Chinese patients.

Authors:  Yuxuan Deng; Qinqin Peng; Sai Yang; Dan Jian; Ben Wang; Yingxue Huang; Hongfu Xie; Ji Li
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.